In what could be a breakthrough for the millions worldwide suffering from age-related eye disorders, scientists have found that drugs could be successfully administered by eye drops rather than unpleasant and expensive eye injections.
The current treatment of injecting drugs into the eye is uncomfortable, detested by patients and often needs repeated monthly injections in hospital for as long as 24 consecutive months.
The new research demonstrates that it is possible to create formulations of tiny nanoparticles loaded with the age-related macular degeneration (AMD) drug Avastin and deliver significant concentrations to the back of the eye.
"The development of eye drops that can be safely and effectively used in patients would be a magic bullet - a huge breakthrough in the treatment of AMD and other debilitating eye disorders," said professor Francesca Cordeiro from the Institute of Ophthalmology at the University College London.
One in five people over 75 have age-related macular degeneration worldwide.
Effective delivery of drugs to the retina of the eye is considered one of the most challenging areas in drug development in ophthalmology owing to the presence of anatomical barriers.
The researchers showed in animal models a formulation system to get substances including Avastin across the barriers in the eye and transport them across the cells of the cornea.
"All the components we used are safe and well established in the field, meaning we could potentially move quite quickly to get the technology into trials in patients," added Ben Davis from the university's institute of ophthalmology.
The research was published in nanotechnology journal Small.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
